Eli Lilly updated its pipeline in late February 2026. The company reported Phase 3 data for orforglipron, an oral GLP-1 candidate. The Zepbound KwikPen received a label expansion.
The EMA issued positive guidance for Olumiant. Omvoh reported durable results. These updates diversify cardiometabolic and immunology franchises beyond injectable GLP-1 drugs.
The pipeline supports Lilly's premium valuation and reduces reliance on blockbuster drugs. Orforglipron's progress strengthens Lilly's cardiometabolic market leadership.